Ocata Therapeutics Inc. (OCAT) 7.22 $OCAT Ocata
Post# of 64200
Posted On: 02/28/2015 8:06:33 PM
Ocata Therapeutics Inc. (OCAT) 7.22 $OCAT
Ocata Therapeutics To Trade On Nasdaq Global Market: Can The Bulls Finally Rejoice?
Biotech Research Group - at Seeking Alpha - Thu Feb 26, 8:33PM CST
OCAT: 7.22 (-0.08)
NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
OCAT: 7.22 (-0.08), VCEL: 3.60 (unch), PSTI: 3.04 (-0.01), NBS: 3.76 (-0.07), GSK: 47.42 (-0.42), IMUC: 0.57 (-0.02), KITE: 65.44 (-2.05), BAX: 69.15 (+0.48), ONCE: 57.59 (-2.66), JUNO: 46.92 (-0.68), ATHX: 2.59 (+0.02), CUR: 3.76 (-0.02)
Ocata terminates equity offering
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 6:07AM CST
OCAT: 7.22 (-0.08)
Ocata Therapeutics Withdraws Offering of Common Stock
Business Wire - Wed Feb 11, 3:44PM CST
Ocata Therapeutics, Inc. (OTCBB: OCAT), a clinical stage biotechnology company developing regenerative ophthalmology therapeutics, today announced that it has withdrawn its previously announced public offering of 10,000,000 shares of common stock under its shelf registration statement given current market conditions.
OCAT: 7.22 (-0.08)
Ocata Therapeutics to Present at 17th Annual BIO CEO & Investor Conference
Business Wire - Wed Feb 04, 8:12AM CST
Ocata Therapeutics, Inc. ("Ocata"; OTCBB: OCAT), a leader in the field of regenerative ophthalmology, today announced that Paul Wotton, Ph.D., President and Chief Executive Officer, will present a company overview at the 17th Annual BIO CEO and Investor Conference on Monday, February 9, 2015 at 9:30 a.m. ET in New York City.
OCAT: 7.22 (-0.08)
Ocata Therapeutics names John Heffernan as VP of Manufacturing
M2 - Wed Feb 04, 5:24AM CST
Ophthalmology company Ocata Therapeutics (OTCBB:OCAT) revealed on Tuesday the addition of John Heffernan as vice president of its Manufacturing.
OCAT: 7.22 (-0.08)
Ocata Therapeutics Appoints John Heffernan, Vice President of Manufacturing
Business Wire - Tue Feb 03, 3:10PM CST
Ocata Therapeutics, Inc. ("Ocata"; OTCBB: OCAT), a leader in the field of regenerative ophthalmology, today announced the appointment of John Heffernan, a pharmaceutical industry veteran, to the newly created position of Vice President of Manufacturing. Mr. Heffernan has a breadth of experience in all facets of manufacturing in the cell therapy space.
OCAT: 7.22 (-0.08)
Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure
M2 - Tue Feb 03, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/lb556t/regenerative) has announced the addition of the "Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure" report to their offering. Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets, approaches and biology are discovered. Improved health care, nutrition and preventive medicine in the last few decades have all helped in increasing life expectancy WW. However, this has not translated in any reduction in the incidences or prevalence of chronic or critical illnesses! On the contrary, the incidence of chronic diseases like diabetes, obesity, arthritis etc. as well as cancer and the maladies associated with aging (dementia, Alzheimer's etc.) are on the rise. Consequently the pharma industry continues to grow and is projected to achieve sales in excess of the trillion dollar mark by 2020. By the next decade, one field which is poised to bring a paradigm change in the way diseases are treated is the Stem cell therapy/Regenerative Medicine space. The number of companies and products in the clinic has reached a critical mass, warranting a close watch by those interested in keeping pace with the development of new medicines. This report describes the key growth drivers and reasons for why this sector is poised for the "golden dawn" and forecasts that in the coming years, the translation of stem cell research to the clinic and market and Stem Cell Technologies Will Begin to Break Through by 2017. Key Topics Covered: 1. Executive summary 2. Introduction 3. Tough Choice- Autologous vs. Allogenic " Therapies 4. Regulatory Scenario 5. Marketed Cell based/Stem Cell Products 6. Progress and Challenges 7. Merger and Acquisition- Gaining Momentum in Regenerative Space 8. Progress in Specific Therapy Areas Companies Mentioned - CESCA Therapeutics Inc. [KOOL] - JCR Pharmaceuticals [4552:JP] - Japan Tissue Engineering Co., Ltd [7774:JP] - Medipost Co. Ltd [078160:KS] - Mesoblast Ltd [MSB:AU] - OCATA Therapeutics Inc. [OCAT] - Orgenesis [ORGS] - Pluristem Therapeutics Inc [PSTI:IT] - TiGenix NV [ TIG:BB] For more information visit http://www.researchandmarkets.com/research/lb...generative
KOOL: 0.91 (unch), OCAT: 7.22 (-0.08), PSTI: 3.04 (-0.01)
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
OCAT: 7.22 (-0.08), ITEK: 6.02 (-0.03), NBS: 3.76 (-0.07), FOMX: 8.96 (-0.09), AERI: 28.12 (-0.49), OCUL: 35.77 (+0.71), AGN: 232.74 (+0.34), CANF: 4.50 (-0.17), ACAD: 37.97 (+0.19), GILD: 103.53 (-0.66), MRK: 58.54 (-0.42), TEVA: 57.02 (+0.53), OHRP: 7.69 (-0.23), CBMG: 29.99 (-0.01)
Vericel Corporation Names Three New Board Members
Marketwired - Wed Jan 07, 7:45AM CST
Vericel Corporation (NASDAQ: VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the appointment of three new members to the company's board of directors: Steven C. Gilman, Ph.D., executive vice president and chief scientific officer of Cubist Pharmaceuticals; Kevin F. McLaughlin, senior vice president and chief financial officer of Acceleron Pharma; and Paul Wotton, Ph.D., president and chief executive officer of Ocata Therapeutics.
OCAT: 7.22 (-0.08), CBSTZ: 0.06 (unch), VCEL: 3.60 (unch), XLRN: 40.63 (-0.37)
The Butterfly Effect: Advanced Cell Technology Becomes Ocata Therapeutics (OCAT)
Scrying Biotech - at Seeking Alpha - Mon Dec 08, 8:58AM CST
OCAT: 7.22 (-0.08)
Ocata Therapeutics Announces Proposed Underwritten Offering of Common Stock
Business Wire - Tue Dec 02, 3:10PM CST
Ocata Therapeutics, Inc. (OTCBB: OCAT), a clinical stage biotechnology company developing regenerative ophthalmology therapeutics, today announced its intention to offer and sell 10,000,000 shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement. The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. As part of this offering, Ocata Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock.
OCAT: 7.22 (-0.08)
Ocata Therapeutics to Present at 26th Annual Piper Jaffray Health Care Conference
Business Wire - Tue Nov 25, 8:19AM CST
Ocata Therapeutics, Inc., (OTCBB: OCAT) today announced that Paul Wotton, Ph.D., President and Chief Executive Officer, will present a company overview at the 26th Annual Piper Jaffray Health Care Conference on Tuesday, December 2, 2014 at 9:30 a.m. EST in New York City.
OCAT: 7.22 (-0.08)
Ocata Therapeutics Receives Advanced Therapy Medicinal Product Designation from the European Medicines Agency
Business Wire - Mon Nov 24, 8:22AM CST
Ocata Therapeutics, Inc., (OTCBB:OCAT) today announced that it has been granted Advanced Therapy Medicinal Product (ATMP) designation for its RPE therapy for macular degeneration. This designation is an essential step in allowing companies to commercialize products effectively across the European Union.
OCAT: 7.22 (-0.08)
A Timely Interview With BioTime's CEO And His Chief Commercial Officer
JMY Investments - at Seeking Alpha - Mon Nov 17, 10:39AM CST
OCAT: 7.22 (-0.08), BTX: 4.20 (-0.07), STEM: 1.12 (+0.03)
Advanced Cell Technology Changes Name to Ocata Therapeutics
Business Wire - Fri Nov 14, 8:02AM CST
Advanced Cell Technology, Inc., (OTCBB: OCAT) today announced the change of its company name to Ocata Therapeutics, Inc., effective immediately. The change, which has been approved by the Company's shareholders, reflects the Company's focus on the development of regenerative cell therapeutics for the treatment of ophthalmic diseases. "Ocata" is a Native American name for "healer," a term associated with repair and regeneration as opposed to merely slowing the progression of disease, or treatment of symptoms.
OCAT: 7.22 (-0.08)
Ocata Therapeutics To Trade On Nasdaq Global Market: Can The Bulls Finally Rejoice?
Biotech Research Group - at Seeking Alpha - Thu Feb 26, 8:33PM CST
OCAT: 7.22 (-0.08)
NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
OCAT: 7.22 (-0.08), VCEL: 3.60 (unch), PSTI: 3.04 (-0.01), NBS: 3.76 (-0.07), GSK: 47.42 (-0.42), IMUC: 0.57 (-0.02), KITE: 65.44 (-2.05), BAX: 69.15 (+0.48), ONCE: 57.59 (-2.66), JUNO: 46.92 (-0.68), ATHX: 2.59 (+0.02), CUR: 3.76 (-0.02)
Ocata terminates equity offering
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 6:07AM CST
OCAT: 7.22 (-0.08)
Ocata Therapeutics Withdraws Offering of Common Stock
Business Wire - Wed Feb 11, 3:44PM CST
Ocata Therapeutics, Inc. (OTCBB: OCAT), a clinical stage biotechnology company developing regenerative ophthalmology therapeutics, today announced that it has withdrawn its previously announced public offering of 10,000,000 shares of common stock under its shelf registration statement given current market conditions.
OCAT: 7.22 (-0.08)
Ocata Therapeutics to Present at 17th Annual BIO CEO & Investor Conference
Business Wire - Wed Feb 04, 8:12AM CST
Ocata Therapeutics, Inc. ("Ocata"; OTCBB: OCAT), a leader in the field of regenerative ophthalmology, today announced that Paul Wotton, Ph.D., President and Chief Executive Officer, will present a company overview at the 17th Annual BIO CEO and Investor Conference on Monday, February 9, 2015 at 9:30 a.m. ET in New York City.
OCAT: 7.22 (-0.08)
Ocata Therapeutics names John Heffernan as VP of Manufacturing
M2 - Wed Feb 04, 5:24AM CST
Ophthalmology company Ocata Therapeutics (OTCBB:OCAT) revealed on Tuesday the addition of John Heffernan as vice president of its Manufacturing.
OCAT: 7.22 (-0.08)
Ocata Therapeutics Appoints John Heffernan, Vice President of Manufacturing
Business Wire - Tue Feb 03, 3:10PM CST
Ocata Therapeutics, Inc. ("Ocata"; OTCBB: OCAT), a leader in the field of regenerative ophthalmology, today announced the appointment of John Heffernan, a pharmaceutical industry veteran, to the newly created position of Vice President of Manufacturing. Mr. Heffernan has a breadth of experience in all facets of manufacturing in the cell therapy space.
OCAT: 7.22 (-0.08)
Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure
M2 - Tue Feb 03, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/lb556t/regenerative) has announced the addition of the "Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure" report to their offering. Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets, approaches and biology are discovered. Improved health care, nutrition and preventive medicine in the last few decades have all helped in increasing life expectancy WW. However, this has not translated in any reduction in the incidences or prevalence of chronic or critical illnesses! On the contrary, the incidence of chronic diseases like diabetes, obesity, arthritis etc. as well as cancer and the maladies associated with aging (dementia, Alzheimer's etc.) are on the rise. Consequently the pharma industry continues to grow and is projected to achieve sales in excess of the trillion dollar mark by 2020. By the next decade, one field which is poised to bring a paradigm change in the way diseases are treated is the Stem cell therapy/Regenerative Medicine space. The number of companies and products in the clinic has reached a critical mass, warranting a close watch by those interested in keeping pace with the development of new medicines. This report describes the key growth drivers and reasons for why this sector is poised for the "golden dawn" and forecasts that in the coming years, the translation of stem cell research to the clinic and market and Stem Cell Technologies Will Begin to Break Through by 2017. Key Topics Covered: 1. Executive summary 2. Introduction 3. Tough Choice- Autologous vs. Allogenic " Therapies 4. Regulatory Scenario 5. Marketed Cell based/Stem Cell Products 6. Progress and Challenges 7. Merger and Acquisition- Gaining Momentum in Regenerative Space 8. Progress in Specific Therapy Areas Companies Mentioned - CESCA Therapeutics Inc. [KOOL] - JCR Pharmaceuticals [4552:JP] - Japan Tissue Engineering Co., Ltd [7774:JP] - Medipost Co. Ltd [078160:KS] - Mesoblast Ltd [MSB:AU] - OCATA Therapeutics Inc. [OCAT] - Orgenesis [ORGS] - Pluristem Therapeutics Inc [PSTI:IT] - TiGenix NV [ TIG:BB] For more information visit http://www.researchandmarkets.com/research/lb...generative
KOOL: 0.91 (unch), OCAT: 7.22 (-0.08), PSTI: 3.04 (-0.01)
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
OCAT: 7.22 (-0.08), ITEK: 6.02 (-0.03), NBS: 3.76 (-0.07), FOMX: 8.96 (-0.09), AERI: 28.12 (-0.49), OCUL: 35.77 (+0.71), AGN: 232.74 (+0.34), CANF: 4.50 (-0.17), ACAD: 37.97 (+0.19), GILD: 103.53 (-0.66), MRK: 58.54 (-0.42), TEVA: 57.02 (+0.53), OHRP: 7.69 (-0.23), CBMG: 29.99 (-0.01)
Vericel Corporation Names Three New Board Members
Marketwired - Wed Jan 07, 7:45AM CST
Vericel Corporation (NASDAQ: VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the appointment of three new members to the company's board of directors: Steven C. Gilman, Ph.D., executive vice president and chief scientific officer of Cubist Pharmaceuticals; Kevin F. McLaughlin, senior vice president and chief financial officer of Acceleron Pharma; and Paul Wotton, Ph.D., president and chief executive officer of Ocata Therapeutics.
OCAT: 7.22 (-0.08), CBSTZ: 0.06 (unch), VCEL: 3.60 (unch), XLRN: 40.63 (-0.37)
The Butterfly Effect: Advanced Cell Technology Becomes Ocata Therapeutics (OCAT)
Scrying Biotech - at Seeking Alpha - Mon Dec 08, 8:58AM CST
OCAT: 7.22 (-0.08)
Ocata Therapeutics Announces Proposed Underwritten Offering of Common Stock
Business Wire - Tue Dec 02, 3:10PM CST
Ocata Therapeutics, Inc. (OTCBB: OCAT), a clinical stage biotechnology company developing regenerative ophthalmology therapeutics, today announced its intention to offer and sell 10,000,000 shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement. The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. As part of this offering, Ocata Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock.
OCAT: 7.22 (-0.08)
Ocata Therapeutics to Present at 26th Annual Piper Jaffray Health Care Conference
Business Wire - Tue Nov 25, 8:19AM CST
Ocata Therapeutics, Inc., (OTCBB: OCAT) today announced that Paul Wotton, Ph.D., President and Chief Executive Officer, will present a company overview at the 26th Annual Piper Jaffray Health Care Conference on Tuesday, December 2, 2014 at 9:30 a.m. EST in New York City.
OCAT: 7.22 (-0.08)
Ocata Therapeutics Receives Advanced Therapy Medicinal Product Designation from the European Medicines Agency
Business Wire - Mon Nov 24, 8:22AM CST
Ocata Therapeutics, Inc., (OTCBB:OCAT) today announced that it has been granted Advanced Therapy Medicinal Product (ATMP) designation for its RPE therapy for macular degeneration. This designation is an essential step in allowing companies to commercialize products effectively across the European Union.
OCAT: 7.22 (-0.08)
A Timely Interview With BioTime's CEO And His Chief Commercial Officer
JMY Investments - at Seeking Alpha - Mon Nov 17, 10:39AM CST
OCAT: 7.22 (-0.08), BTX: 4.20 (-0.07), STEM: 1.12 (+0.03)
Advanced Cell Technology Changes Name to Ocata Therapeutics
Business Wire - Fri Nov 14, 8:02AM CST
Advanced Cell Technology, Inc., (OTCBB: OCAT) today announced the change of its company name to Ocata Therapeutics, Inc., effective immediately. The change, which has been approved by the Company's shareholders, reflects the Company's focus on the development of regenerative cell therapeutics for the treatment of ophthalmic diseases. "Ocata" is a Native American name for "healer," a term associated with repair and regeneration as opposed to merely slowing the progression of disease, or treatment of symptoms.
OCAT: 7.22 (-0.08)
(0)
(0)